RxDoctor Payments Data

Roger Charles, MD

Gastroenterology · Weston, FLNPI 1245323062

Payments from drug & device makers

$3,093in general payments, 2019–2025

Across 136 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boston Scientific$575
  • Ipsen Biopharmaceuticals, Inc$229
  • Takeda Pharmaceuticals U.S.A., Inc.$213
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$104
  • Ardelyx, Inc.$100
  • plus $740 from 15 others

What the payments were for

  • Food & beverage$3,093100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,093 in reported general payments places this provider in the 45th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$61,596
Medicare patients
299
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab30$819,254
Cimzia (2 Pack)Certolizumab Pegol13$152,474
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres12$78,858
LinzessLinaclotide23$17,832
Mesalamine21$17,356
Octreotide Acetate25$7,368
Colestipol Hcl37$5,896
DexilantDexlansoprazole12$3,535
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg98$2,006
Pantoprazole Sodium95$1,561
Omeprazole68$1,320
Esomeprazole Magnesium13$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$75$819,25430 claims
AbbVieLinzess$1,133$17,83223 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$213$3,53512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →